Skip to content

Auricular Stimulation for Relief of Stress and Anxiety During COVID-19 Epidemic

Auricular Stimulation (AS) vs. "Waiting List" for Relief of Stress and Anxiety in Health Care Workers During COVID-19 Pandemic - a Prospective Controlled Investigation

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04703907
Acronym
AA_COVID_19
Enrollment
62
Registered
2021-01-11
Start date
2020-12-03
Completion date
2021-08-30
Last updated
2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress and Anxiety

Brief summary

The aim of the study is to evaluate whether auricular stimulation (percutaneous sensory stimulation of cranial nerves) as compared vs. no intervention (waiting list) reduces stress and anxiety in health care providers, working at the time of COVID-19 pandemic at the University Medicine of Greifswald.

Interventions

Auricular "acupuncture-like" stimulation (percutaneous sensory stimulation of cranial nerves)

Sponsors

University Medicine Greifswald
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective investigation during 15 weeks of treatment for each participant with "waiting list" control group (no intervention). Waiting group will receive the intervention (auricular stimulation) after 15 weeks of investigation.

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Medical care workers at the University Medicine of Greifswald 2. Experiencing stress and anxiety in connection with COVID-19 pandemic 3. Participants without previous anxiolytic medication 4. Ability to understand and fill in the structured questionnaire (Appendix D \& E) 5. Written informed consent

Exclusion criteria

1. Recidivist alcoholics 2. Local auricular skin infection 3. Pregnant or lactating women 4. Participants with prosthetic or damaged cardiac valves and mitral valve prolaps (risk of bacterial endocarditis according to guidelines of AHA) 5. Participants who are unable to understand the consent form 6. History of psychiatric disease

Design outcomes

Primary

MeasureTime frameDescription
Anxiety15 weeks of investigationState anxiety

Secondary

MeasureTime frame
Trait anxietyBefore and after 15 weeks of intervention application
Sleep quality15 weeks of investigation

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026